Novartis
Novartis doubles down on Cosentyx’s efficacy in psoriasis with extensive real-world data
September 13, 2018Research and Development Cosentyx, Novartis, pharma, psoriasis
Novartis was yet another company to reveal new data on a psoriasis drug at the European Academy of Dermatology and …
Teva names new President, TAPI and Biologics Operations
September 12, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing BMS, Novartis, Teva, appointment
Israeli generic drug specialist Teva has announced its appointment of John Nason in a multi-faceted role as President of Teva …
Novartis eyecare unit Alcon to set up new HQ in Geneva, Switzerland
September 11, 2018Manufacturing and Production Alcon, Novartis, eye care, pharma
Alcon, the eyecare unit of Novartis, is set to move to a new home next year, after its parent company …
Novartis sells key Sandoz US portfolios to Aurobindo for $1bn
September 6, 2018Sales and Marketing Aurobindo, Novartis, Sandoz, pharma
Novartis has revealed it is to sell the dermatology and generic US oral solids portfolios of its generics arm Sandoz …
Novartis’ CAR T therapy Kymriah to become available on the NHS
September 5, 2018Research and Development CAR T, CAR-T, Gilead, Kymriah, NHS, Novartis
Novartis’ Kymriah is set to become the first CAR T therapy to become available on the NHS after it was …
Top Ten most popular articles on Pharmafile.com this week
August 31, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Eisai, Medicare, Novartis, UK, brexit, generics, king bio, pharma, top ten
Eight months of 2018 down – where has the year gone? As we move from August into September, and a …
Novartis to create 450 new jobs at Aargau site after Kymriah thumbs up
August 29, 2018Research and Development CAR T, CAR-T, Jobs, Kymriah, Novartis
Swiss multinational Novartis is set to create up to 450 new jobs following the investment of 90 million Swiss Francs …
Novartis’ Kymriah & Gilead’s Yescarta become first EU-approved CAR T therapies
August 28, 2018Manufacturing and Production, Sales and Marketing CAR T, CAR-T, Cancer, EU, Gilead, Kymriah, Novartis, UK, Yescarta, blood cancer, pharma
Almost one full year since the treatment was given a “historic” approval in the US, Novartis’ CAR T therapy Kymriah …
Novartis’ investigational combo impresses in breast cancer sub-group
August 23, 2018Research and Development Cancer, Novartis, breast cancer, fulvestrant, pharma
Novartis has revealed positive new data for its investigational alpha-specific PI3K inhibitor BYL719 (alpelisib) combined with fulvestrant in the treatment …
Novartis hands over global rights for two oncology drugs to Shanghai’s Laekna
August 2, 2018Sales and Marketing Cancer, Laekna, Novartis, oncology, pharma
Novartis has revealed that it has jettisoned two of its clinical stage oncology products along with exclusive global development and …
Novartis migraine prevention drug scores EU approval
July 31, 2018Manufacturing and Production, Sales and Marketing Aimovig, Europe, Novartis, migraine, pharma
Novartis is celebrating the news that its calcitonin gene-related peptide receptor (CGRP-R) pathway therapy Aimovig (erenumab) has been approved by …
Top Ten most popular articles on Pharmafile.com this week
July 20, 2018Medical Communications GSK, ICR, J&J, JJ, Novartis, Trump, brexit, top 10
As Brexit negotions have hit a stalemate this week, the United Kingdom’s exit from the European Union has hit the …
Merck joins Pizer and Novartis in reducing drug prices
July 20, 2018Medical Communications Merck, Novartis, Pfizer, Trump, Twitter, price hikes
Merck & Co. have joined Pfizer and Novartis in halting price increases on medicines in the United States. The American …
Donald Trump thanks Novartis for halting price hikes
July 20, 2018Medical Communications Novartis, Pfizer, Trump, Twitter, price hikes
Donald Trump has thanked Swiss multinational Novartis for halting price hikes on prescription drugs in the United States. The US …
Novartis buys eczema drug in €95m deal
July 19, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Novartis, deal, eczema, experimental, patent
Novartis has agreed to buy the rights for a novel antibody MOR106 from the Belgo-Dutch pharmaceutical research company Galapagos and …
Latest content
Santen joins inaugural Global Summit for Eye Health as partner
